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To help understand the potential impact of bacterial coinfection during pandemic influenza periods, we undertook a far-reaching
review of the existing literature to gain insights into the interaction of influenza and bacterial pathogens. Reports published
between 1950 and 2006 were identified from scientific citation databases using standardized search terms. Study outcomes related
to coinfection were subjected to a pooled analysis. Coinfection with influenza and bacterial pathogens occurred more frequently
in pandemic compared with seasonal influenza periods. The most common bacterial coinfections with influenza virus were due to
S. pneumoniae, H. influenzae, Staphylococcus spp., and Streptococcus spp. Of these, S. pneumoniae was the most common cause of
bacterial coinfection with influenza and accounted for 40.8% and 16.6% of bacterial coinfections during pandemic and seasonal
periods, respectively. These results suggest that bacterial pathogens will play a key role in many countries, as the H1N1(A) influenza
pandemic moves forward. Given the role of bacterial coinfections during influenza epidemics and pandemics, the conduct of welldesigned field evaluations of public health measures to reduce the burden of these common bacterial pathogens and influenza in
at-risk populations is warranted.

1. Introduction
Worldwide, seasonal influenza causes an estimated one million deaths, and Streptococcus pneumoniae is associated with
approximately 875,000 deaths among children and ∼1.1 million deaths among adults each year [1–3]. Influenza and S.
pneumoniae account for a large proportion of total respiratory disease morbidity and mortality. In addition, bacterial coinfection due to pathogens such as S. pneumoniae is a
recognized complication of both upper and lower respiratory
tract disease due to influenza [4, 5].

With the continued spread of H1N1 influenza virus
and the declaration of a global H1N1 influenza pandemic,
the impact of this virus may greatly increase in coming
months—particularly in populations where there is limited
access to health care. In recent years, as pandemic preparedness activities have advanced throughout the world, the treatment, the management, the and prevention of bacterial coinfections (e.g., S. pneumoniae, Haemophilus influenzae type b
[Hib]) have garnered increasing attention [6]. To help understand the potential impact of vaccination against coinfection
during pandemic influenza periods, we undertook a broad
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review of the existing literature that provides new insights
into the interaction of influenza and bacterial pathogens.

2. Methods
2.1. Searching Strategy. In this study, we sought to examine
the available evidence from published studies to describe the
frequency of bacterial etiologies responsible for coinfection
with influenza virus. Studies of the association between
influenza and bacterial coinfections, including the impact of
S. pneumoniae vaccines, were identified using standardized
search algorithms for systematic reviews [7, 8]. Published
articles in the English and non-English literature were sought
through systematic searching of local and international
electronic databases. To facilitate identification of published
literature, we accessed PubMed (United States), Chinese BioMedicine (CBM, China), OVID (Ovid Technologies, Inc.,
United States), ISI Web of Knowledge (Thomson Reuters,
United States), and Korean Medline (KoreaMed, Korea).
The review included articles published between 1918 and
2006. Due to limitations in currently available electronic
databases, articles published before 1950 were identified
from publication reference lists obtained from scientific
periodicals, books, and other publications. Because of the
limited availability of electronic citations for studies related
to the first influenza pandemic in the 20th century, we
performed a hand search covering all issues of JAMA and
the Lancet published in 1918 and 1919. Studies of pandemic
influenza were identified based on text or data reported in
publications that referred to patients who became ill during
any of the influenza pandemics of 1918, 1957, or 1968.
To conduct the literature search, medical subject heading (MeSH) terms (influenza, human, pneumonia, bacteria, pneumococcal infections, superinfection, pneumococcal
infections, complications, pandemic, and immunization)
and free words (coinfection, polymicrobial, predispose, and
bacterial coinfection) were used to identify reports. This list
of MeSH terms and free words was evaluated in a pilot study
to confirm their ability to identify relevant scientific publications. Combinations of these MeSH terms and free words
were then constructed for literature searching. In addition,
the search terms and their combinations were translated into
standard Korean and Chinese medical terminology prior to
searching non-English electronic databases.
2.2. Reviewing Strategy. Using the databases identified above,
all studies published from 1950 to 2006 in English and nonEnglish languages were tabulated for initial review. Studies
were excluded from this paper if they met one of the following criteria: (a) had no extractable data or studies limited
to single patients (e.g., case reports), (b) had no dates of
collection for data reported. Endnote (version X, Thomson,
Inc., Philadelphia, USA) bibliographic software was used
to create an electronic library of citations identified in our
database searches. PubMed searches were performed using
Endnote software, and references from each search were
imported to Endnote software databases. Study references
that could not be uploaded directly into Endnote software
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(these included references identified in published paper
reference lists or identified through other hand searches)
were entered manually into study reference databases. After
deleting duplicate records, each study was assigned a unique
identification code to enable tracking of reviews and analysis.
Each citation was then screened by reviewing the text for
all report titles and abstracts. Studies that did not meet the
inclusion criteria in this study were excluded from the fulltext review. All remaining papers and reports underwent
full-text review by two independent study reviewers. From
each study, the following information was abstracted: design
of study, geographic location of study, study time period
(month, year), study duration (months or years), total
number of study patients, number of patients with bacterial
coinfections, types of bacterial pathogens responsible for
coinfection, as well as method of influenza virus and bacterial
coinfection diagnosis. Kappa (κ) statistics were calculated
for the interreviewer agreement during the title/abstract and
full-text evaluations using Stata 9.2 (StataCorp LP, College
Station, Tex). Reports that yielded conflicting information
among study reviewers were discussed with coinvestigators
to obtain consensus.
2.3. Definitions. To identify a case of suspected influenza
virus infection, the study had to report patients as having at
least one or more of the following clinical signs or symptoms:
rapid onset of chills and high fever, frequent epistaxis,
myalgia and arthralgia, prostration, pharyngitis without tonsillitis, rhinorrhea and cough with or without sputum, and
with or without evidence of chest radiograph abnormalities.
A diagnosis of confirmed influenza virus infection was identified when, in addition to the symptoms mentioned above,
there was also evidence on laboratory testing of influenza
virus infection from (a) a rapid diagnostic test, (b) enzyme
immunoassay, (c) isolation of the virus in tissue-cell culture,
(d) direct or indirect immunofluorescent antibody staining,
(e) reverse transcriptase-polymerase chain reaction (RTPCR) analysis, or (f) immunohistochemistry. Influenza
pneumonia was defined by evidence of an acute pulmonary
infiltrate on the chest radiograph. A bacterial coinfection
was defined by a positive laboratory test for any bacterial
pathogen in a patient with evidence of either clinical or
laboratory-confirmed influenza.
2.4. Data Analysis. All studies included in this paper underwent data extraction by trained study personnel and data
were entered into an MS Excel (Microsoft, Inc., Redmond,
Wash, USA) database. SAS statistical software was used for
analysis in this study (SAS Institute Inc., Cary, NC, USA).
To take into account variations in study designs, diagnostic
methods, study periods, and other study characteristics,
we utilized a random-eﬀects model to calculate the point
estimates of log-transformed proportions (and rates) with
their associated 95% confidence intervals [9–11]. The use
of the random-eﬀects model allowed for the inclusion of
covariates to reduce heterogeneity and for more specific
recommendations to be made from this analysis.
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Studies were grouped into the following design categories: (a) descriptive studies (e.g., case series, cross-sectional surveys, or surveillance studies), (b) analytic studies
(e.g., cohort or case-control studies), and (c) interventional
studies (e.g., clinical therapeutic or vaccine trials). To explore
the potential association between influenza and bacteria
infections, studies were also stratified by type of bacterial
pathogen, pandemic period, and type of sample for bacteria
culture. The Kruskal-Wallis test was applied (using 0.05 as
the level of significance) to compare the diﬀerence of proportions of coinfection caused by S. pneumoniae, H. influenzae,
Streptococcus spp., and Staphylococcus spp. during seasonal
influenza and pandemic influenza periods.
This study was reviewed and approved by the International Vaccine Institute Institutional Review Board.

3. Results
The initial search identified 11,106 influenza and bacteria infection-related citations. After exclusion of duplicate
records, a total of 9,587 and 674 studies were excluded using
review of title/abstract and full-text information, respectively. Most of studies were excluded due to no extractable
data (Figure 1). The interobserver agreement was 86.3%
and 92.0% (P < .05) for title/abstract and full-text screen,
respectively. Seventy-one published studies which met the
inclusion and exclusion criteria for this paper were included
in the final analysis. Of these reports, 65 studies (91.5%)
were descriptive design. Most bacterial infections (93.0%)
were diagnosed with culture results, compared to 31.0%
cultural diagnosis of influenza (Table 1). Among the 71
articles included in the final analysis, 56 reports presented
the data on the association between influenza and bacterial
coinfection. Of these, 39 (69.6%) reports originated from
either the USA or the UK with the remainder largely from
Japan and Spain (Appendix).
A pooled analysis showed that the most common bacterial organisms causing coinfections were S. pneumoniae, H.
influenzae, Staphylococcus spp., and Streptococcus spp. For all
bacterial coinfections, rates of coinfection during pandemic
influenza transmission periods were higher than for seasonal
influenza (Table 2). S. pneumoniae was the most commonly
reported (40.8%) bacterial pathogen causing coinfections
with influenza during pandemic periods. H. influenzae
caused coinfection in 12.9% of patients with influenza,
while Staphylococcus spp. and Streptococcus spp. was found
in 25.0% and 15.7% of patients, respectively. In addition,
studies of seasonal influenza showed that S. pneumoniae was
the leading cause of bacterial coinfection (pooled average,
16.6%) followed by Staphylocccus spp. (6.2%), H. influenzae
(5.2%), and Streptococcus spp. (1.8%).
We conducted further analysis of bacterial coinfections
reported during three (1918, 1957, and 1968) influenza
pandemic periods (Table 3). Few studies were available from
the 1968 pandemic period, and data from these studies did
not contain suﬃcient patient numbers to permit calculation
of pooled proportions of coinfection. During the 1918
pandemic, S. pneumoniae caused the highest level (56.5%)
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Published reports after searching
N = 11,106
Exclusion of duplicate
reports
N = 755
Reports remaining after excluding duplicates
N = 10,351

Reports excluded with
title screening
N = 9,587
Reports remaining after title screening
N = 764

Reports excluded following
full-text review
N = 674

Reports for which full
text was not available
N = 19

Reports remaining after full-text screening
N = 71

Figure 1: Study flow diagram showing review of reports.

Table 1: Characteristics of studies included in analysis (n = 71).
Studies
(n)

%

Study type
Descriptive
Analytic
Interventional

65
2
4

91.5
2.8
5.6

Study scope
Laboratory-based
Population-based
Hospital-based

1
15
55

1.4
21.1
77.5

Influenza diagnostic methods
Clinical diagnosis
Antigen/antibody detection
RT-PCR

32
16
1

45.1
22.5
1.4

22

31.0

3
2

4.2
2.8

66

93.0

Characteristics

Culture
Bacterial infection diagnostic methods
Clinical diagnosis
Antigen/antibody detection
Culture

Note: RT-PCR, reverse transcription-polymerase chain reaction.
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Table 2: Pooled results of coinfecting bacterial pathogens identified with influenza virus during seasonal and pandemic influenza periods.
Bacteria
S. pneumoniae
H. influenzae
Streptococcus spp.
Staphylococcus spp.

Transmission period

Studies (n)

Seasonal
Pandemic
Seasonal
Pandemic
Seasonal
Pandemic
Seasonal
Pandemic

22
35
10
27
7
27
12
26

Estimates from random eﬀects model
Average % coinfection with influenza virus
95% Confidence interval
a
16.6
7.9–31.6
40.8
30.5–52.0
2.3–11.5
5.2b
12.9
8.3–19.5
1.8c
0.3–9.3
15.7
9.1–25.8
2.3–15.7
6.2d
25.0
15.4–37.8

a

Seasonal versus pandemic pooled average proportion of patients with S. pneumoniae coinfection (P = .008, Kruskal-Wallis test; Bonferonni correction, α =
0.008).
b Seasonal versus pandemic pooled average proportion of patients with H. influenzae coinfection (P = .02, Kruskal-Wallis test; Bonferonni correction, α =
0.008).
c Seasonal versus pandemic pooled average proportion of patients with Streptococcus spp. coinfection (P = .009, Kruskal-Wallis test; Bonferonni correction,
α = 0.008).
d Seasonal versus pandemic pooled average proportion of patients with Staphylococcus spp. coinfection (P = .005, Kruskal-Wallis test; Bonferonni correction,
α = 0.008).
e During seasonal flu period, the proportions of coinfection caused by S. pneumoniae, H. influenzae, Streptococcus spp., and Staphylococcus spp. were diﬀerent.
(P = .009, Kruskal-Wallis test; Bonferonni correction, α = 0.008).
f During pandemic flu period, the proportions of coinfection caused by S. pneumoniae, H. influenzae, Streptococcus spp., and Staphylococcus spp. were diﬀerent.
(P < .0001, Kruskal-Wallis test; Bonferonni correction, α = 0.008).

Table 3: Comparison of coinfection with major bacterial pathogens and influenza by pandemic period (n = 56)a,b .
Bacteria

S. pneumoniae

H. influenzae

Streptococcus spp.

Staphylococcus spp.

Pandemic period

Studies (n)

1918
1957
1968
1918
1957
1968
1918
1957
1968
1918
1957
1968

23
9
3
17
9
1
20
6
1
12
11
3

Estimates from random eﬀects model
Average % coinfection with influenza virus
95% Confidence interval
56.5
45.6–66.8
15.6
8.8–26.0
27.8
2.9–83.2
17.9
9.9–30.3
6.9
4.5–10.5
—
6.3c
21.7
12.9–34.1
4.6
0.6–28.2
—
9.4c
18.8
8.0–38.0
39.7
20.9–62.2
10.3
4.9–20.2

a

Proportions for S. pneumoniae, H. influenzae, Streptococcus spp., and Staphylococcus spp. were diﬀerent (P < .0001, Kruskal-Wallis test; Bonferonni correction,
α = 0.025) during 1918-1919 pandemic.
b Proportions for S. pneumoniae, H. influenzae, Streptococcus spp., and Staphylococcus spp. were diﬀerent (P = .0006, Kruskal-Wallis test; Bonferonni correction,
α = 0.025) during 1957 pandemic.
c Original data.

of coinfection with influenza virus followed by Streptococcus
spp. (21.7%), Staphylococcus spp. (18.8%), and other H.
influenzae (17.9%). In studies around the 1957 pandemic
period, the most common cause of bacterial coinfection with
influenza virus was Staphylococcus spp. (39.7%) followed by
S. pneumoniae (15.6%).
In the studies that contained suﬃcient data for full-text
review and data extraction during pandemic period, the
proportions of organisms causing coinfections were diﬀerent
while calculated by type of specimens utilized for bacterial

diagnosis (Table 4). Studies in which sputum or swab specimens were used for bacterial isolation showed proportions
of coinfection ranging from 13.8% for Staphylococcus spp.,
14.6% for Streptococcus spp., 14.3% for H. influenzae, to
40.8% for S. pneumoniae (Kruskal-Wallis test, P = .0008).
However, among studies that utilized necropsy specimens to
detect coinfection, S. pneumoniae showed the highest rate
(46.5%) of coinfection closely followed by Staphylococcus
spp. (43.0%), Streptococcus spp. (19.6%), and H. influenzae
(17.6%) (Kruskal-Wallis test, P = .02).
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Table 4: Comparison of coinfection with major bacterial pathogens and influenza by specimen type during pandemic influenza periodsa,b .
Bacteria

S. pneumonia

H. influenza

Streptococcus spp.

Staphylococcus spp.

Specimen

Studies (n)

Sputum/swab
Sterile fluid
Necropsy
Sputum/swab
Sterile fluid
Necropsy
Sputum/swab
Sterile fluid
Necropsy
Sputum/swab
Sterile fluid
Necropsy

24
4
12
17
2
9
18
2
12
11
2
11

Estimates from random eﬀects model
Average % coinfection with influenza virus
95% Confidence interval
40.8
30.3–52.3
7.0
2.1–21.4
46.5
24.8–69.7
14.3
8.6–23.1
2.6
0.4–14.6
17.6
6.7–39.1
14.6
7.1–27.5
1.4
0.02–46.4
19.6
9.5–36.2
13.8
7.7–23.4
2.7
0.5–14.1
43.0
20.8–68.5

a

Proportions for S. pneumoniae, H. influenzae, Streptococcus spp. and Staphylococcus spp. were diﬀerent (P = .008, Kruskal-Wallis test: Bonferonni correction,
α = 0.025) while utilized sputum/swab specimens to detect coinfection.
b Proportions for S. pneumoniae, H. influenzae, Streptococcus spp. and Staphylococcus spp. were diﬀerent (P = .02, Kruskal-Wallis test; Bonferonni correction,
α = 0.025) while utilized necropsy specimens to detect coinfection.

4. Discussion
The data synthesized in this paper indicate that S. pneumoniae is the leading cause of bacterial coinfection during
both seasonal and pandemic influenza periods, followed by
Staphylococcus spp., Streptococcus spp., and H. influenzae.
However, other major causes of invasive bacterial diseases
(e.g., Staphylococcus spp.) are close behind S. pneumoniae
as a cause of coinfection with influenza virus. These
data suggest that S. pneumoniae and Staphylococcus spp.
are leading causes of bacterial coinfection with influenza.
Interestingly, bacterial coinfection, as well as the relative
frequency concluded above, was also demonstrated by
several recent studies examining bacterial coinfection during
2009-2010 H1N1 pandemic [12–14]. Notably, the hierarchy
of bacterial coinfections identified in this review of studies
performed during influenza pandemic periods showed the
same order of importance as studies from interpandemic
periods. An important observation from our analysis was
that the proportion of patients with bacterial coinfection was
significantly higher in the pandemic studies compared with
studies conducted during interpandemic periods.
Our review has some limitations. First, because of the
time period covered by this paper and advancement in laboratory methods over the same period, the laboratory identification of influenza virus and bacterial pathogens varied
during the study period. Thus, it is possible that more recent
studies had higher sensitivity or specificity for the detection
of both viruses and bacteria. In addition, it is possible
that other bacterial pathogens may be important but were
undetected due to limitations in the laboratory methods used
during diﬀerent time periods or in diﬀerent countries. In
this paper, we found a limited number of cohort studies
during either seasonal or pandemic influenza periods. As a
result, our analysis could not describe data in a well-defined
cohort of influenza patients who were followed prospectively

to assess rates of bacterial coinfection. Notwithstanding,
the bacterial coinfection and pattern concluded from our
analysis were illustrated again during the recent H1N1 pandemic [12–14]. Second, the findings suggest that bacterial
coinfection is higher in pandemic periods compared to
endemic periods. This observation might be attributable
to additional epidemiologic and clinical eﬀorts that are
carried out during studies falling within pandemic periods
compared with seasonal influenza periods. In fact, out of the
56 studies that provided coinfection data, 34 (60.7%) were
conducted during the pandemic period. An additional 22
(39.3%) studies described the pattern of bacterial coinfection
during seasonal influenza periods. Moreover, most studies
identified in this paper, regardless of whether they were
conducted during pandemic or seasonal influenza periods,
applied hospital-based designs and focused on severely ill
patients with outcomes resulting in hospitalization or death.
Finally, the increasing antimicrobial resistance [15, 16] might
aﬀect the isolation of bacteria. In this analysis, all pandemicrelated studies in this paper were carried out before 1970.
Conversely, out of the 22 seasonal influenza studies, 19
(86.4%) were conducted after 1970. Thus, an underestimation of bacterial coinfection in seasonal influenza studies
may have occurred where population usage of antibiotics was
more prevalent.
Our analysis suggests that public health measures to
reduce the burden of bacterial coinfections is warranted.
In a study of pneumococcal vaccine eﬀectiveness in South
Africa, it appears that immunization with pneumococcal
conjugate vaccine (PCV) in children is associated with
moderate protection against influenza [17]. One potential
explanation of this eﬀect is that PCV reduces mucosal colonization by pneumococcal vaccine serotypes and engenders
herd protection against pneumococcal vaccine serotypes
among unvaccinated individuals. In so doing, PCV indirectly
reduces severe pneumococcal infections that may be more
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susceptible to influenza virus infection. A complementary
explanation may rest in the fact that PCV directly reduces the
burden of severe pneumococcal infections that also reduces
the number of individuals in the vaccinated population who
are susceptible to influenza virus infection. A limited number
of studies have suggested that an excess burden of invasive
pneumococcal disease is associated with seasonal influenza
epidemics. In Sweden [18], a negative binomial model was
used to estimate the excess burden of IPD using influenza and
IPD data between 1994 and 2004 from Swedish surveillance
system. This analysis showed a yearly increase of 72 to 118
cases of IPD attributable to influenza, which corresponded
to 6% to 10% overall per year or 12% to 20% during any
given influenza season. Based on our analysis of coinfection
studies, S. pneumoniae and other bacterial pathogens are
likely to reappear as a major cause of bacterial coinfection
in future influenza pandemics. Therefore, a key question
for policymakers is whether or not vaccines for prevention
of invasive bacterial infections caused by S. pneumoniae
and other pathogens should play a more active role in
helping to prepare countries for pandemic influenza. Given
the likelihood of continuing influenza virus transmission in
present pandemic and bacterial coinfections that occur with
influenza, there is an urgent need to reevaluate the full range
of tools that may mitigate the burden of invasive bacterial
infection, including pneumococcal and Hib vaccines as
well as pharmacologic and nonpharmacologic interventions.
The evaluation of pneumococcal vaccines with or without
influenza vaccine to reduce the burden of coinfections
will require large-scale, carefully designed and appropriately
powered field trials in order to provide high-quality evidence
currently required by public health policymakers.
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